Ascom presents its Digistat suite at Arab Health Exhibition and Congress 2018 (29 Jan – 1 Feb), a healthcare ICT solution with a wide range of applications for caregivers; Recent additions to the Digistat portfolio show its versatile use to increase the efficiency in patient care
DUBAI, United Arab Emirates, Jan 26 (Bernama-GLOBE NEWSWIRE) -- Ascom (SWX:ASCN.SW), the global solutions provider focused on healthcare ICT and mobile workflow solutions, will showcase the sophisticated Digistat suite of clinical data management modules at the Arab Health Exhibition and Congress 2018. Digistat is a suite of software modules that can be configured into numerous solutions especially for ICUs, surgical and OR management, medical device integration, and the centralized display of patient data collected from multiple medical devices. Gianluca Testasecca, Head of Digistat International Sales at Ascom, who will be attending Arab Health Exhibition and Congress 2018, emphasizes that Ascom will focus on recent additions to the Digistat portfolio: “We are, for example, excited to demonstrate the new Ascom Digistat Vitals application. It’s a pioneering app that lets caregivers record vital parameters and perform guided scoring calculation at the bedside. This helps achieve faster, more accurate and more direct registration of vitals into Electronic Medical Records. Double documentation and paper-to-EMR registration are time-intensive and prone to errors and omissions—issues that are addressed by Ascom Digistat Vitals.” This is the fourth time Ascom participates in Arab Health. “The Middle East and Asian markets are increasingly important to Ascom,” comments Testasecca. “There is a growing demand for smart mission-critical solutions. And as healthcare infrastructures develop and mature, there is increasing awareness that our solutions can play a key part in maximizing investment returns while simultaneously contributing to patient safety and satisfaction.” The Ascom stand at Arab Health 2018 is S1. B50 Disclaimer: Availability of products are subject to regulatory clearance. Products may not be available in a particular country or region. Specifications and availability are subject to change without further notice. About Ascom Ascom is a global solutions provider focused on healthcare ICT and mobile workflow solutions. The vision of Ascom is to close digital information gaps allowing for the best possible decisions – anytime and anywhere. Ascom’s mission is to provide mission-critical, real-time solutions for highly mobile, ad hoc, and time-sensitive environments. Ascom uses its unique product and solutions portfolio and software architecture capabilities to devise integration and mobilization solutions that provide truly smooth, complete and efficient workflows for healthcare as well as for industry and retail sectors. Ascom is headquartered in Baar (Switzerland), has subsidiaries in 15 countries and employs around 1,300 people worldwide. Ascom registered shares (ASCN) are listed on the SIX Swiss Exchange in Zurich. This document does not constitute an offer or solicitation to subscribe for, purchase or sell any securities. This document is not being issued in the United States of America or the United Kingdom and should not be distributed in any jurisdiction in a manner where such distribution would not comply with regulatory requirements. In particular, this document may not be distributed into the United States, to United States persons or to publications with a general circulation in the United States. In addition, the securities of Ascom have not been and will not be registered in any jurisdiction outside Switzerland. The securities of Ascom may not be offered, sold or delivered and no solicitation to purchase such securities may be made within the United States or to U.S. persons absent an applicable exemption from the registration requirements of the United States securities laws or within any other jurisdiction and in a manner where such offer, sale, delivery or solicitation might not be in compliance with regulatory requirements (including the United Kingdom). Contact: Adam Jaffe, Marketing Growth Markets, Ascom Phone: +61 411 830 568 Email: [email protected] SOURCE : Ascom Holding AG
0 Comments
TORONTO, Jan 25 (Bernama-GLOBE NEWSWIRE) -- Switzerland is the freest country in the world, having replaced Hong Kong atop the Human Freedom Index, released today by the Fraser Institute and a network of international public policy think-tanks.
The United States inched upwards six spots from 24th to 17th in the index, which uses 79 indicators of personal, civil and economic freedoms to rank 159 countries and jurisdictions worldwide. “The Human Freedom Index measures the degree to which people are free to enjoy civil liberties—freedom of speech, religion, women’s rights, association and assembly and economic freedom,” said Fred McMahon, Dr. Michael A. Walker Research Chair in Economic Freedom at the Fraser Institute and editor of the report. Other notable countries include: Canada (11), Germany (16), Japan (27), France (33), Mexico (73), India (102), Russia (126) and China (130). For the past two years, Hong Kong led the rankings as the freest jurisdiction in the world, largely as a result of the city’s score in economic freedom. “Hong Kong’s fall from the top of the Human Freedom Index this year could indicate China is encroaching on its one-country, two-system relationship and the people of Hong Kong are materially less free because of it,” McMahon said. Crucially, people in freer countries earn more money than those who live in less-free countries. For example, the average per capita income for the top-quartile countries on the index was US$38,871 compared to just US$10,346 for the least-free quartile in 2015, the most recent year of available comparable data in the freedom index. mrem.bernama.com/viewsm.php?idm=31016 DALLAS, Jan 24 (Bernama-BUSINESS WIRE) -- SpotSee, a global internet of things (IoT) connectivity platform and parent company to leading logistics monitoring brands ShockWatch®, SpotBot, ShockLog® OpsWatch, ShockTrak and WarmMark®, orchestrated a raid of suspected ShockWatch product counterfeiters in Taiwan on October 26, 2017. The goods seized, primarily ShockWatch counterfeit products, infringe on trademarks and patents and are considered fraudulent. Counterfeit and knock-off materials, which do not perform to SpotSee specifications, have been found to cause false activations and increased damage claims for customers. “We take the illegal use of our intellectual property very seriously, and we take swift action to stop the unauthorized use of our name, designs and trademarks,” said Tony Fonk, CEO, SpotSee. “It’s important we stop this fraud because it directly costs our customers money.” Both manufacturers and distributors of counterfeit SpotSee products will be held accountable as SpotSee actively works to put an end to all activities involving the illegal use of its brand. The penalties for counterfeiting can be up to five years of imprisonment and/or a fine of NT $2,000,000 (approximately USD $66,666). To further address the counterfeit issue, SpotSee has designed authentication methods such as serialization and QR codes into their newest line of indicators known as the ShockWatch ShockDot. “The ShockDot allows customers to validate that they purchased a genuine product in addition to other benefits such as 50 percent more indication area and 360-degree activation,” said Angela Kerr, vice president of product management, SpotSee. “We are taking a legal and an innovative, product-based approach to solving this problem.” ShockWatch indicators, manufactured by SpotSee, show when a product or asset has been mishandled in the supply chain. Incorrect activation can misrepresent that a package or shipment has been mishandled, when it may not have been. Alternatively, the counterfeit or knock-off indicators may not go off at all when mishandling actually occurs. SpotSee customers who are concerned they may be victims of counterfeit products should contact SpotSee at +1 214-736-4578. WORLD HEALTH ORGANIZATION GRANTS PREQUALIFICATION TO BHARAT BIOTECH'S ROTAVIRUS VACCINE, ROTAVAC®25/1/2018 NEW DELHI, Jan 25 (Bernama-BUSINESS WIRE) -- Bharat Biotech today announced that the World Health Organization (WHO Geneva) has awarded prequalification to the developing world’s first rotavirus vaccine, ROTAVAC®.
WHO Prequalification is necessary for UN agencies and Gavi, the Vaccine Alliance to purchase the vaccine in partnership with developing countries and will help accelerate availability of the ROTAVAC® to the developing countries with the highest burden of disease. India has introduced ROTAVAC® into its national immunization program during 2016, with ~35 million doses delivered till date. Rotavirus is the leading cause of severe diarrhea among children less than five years of age around the world, resulting in ~215,000 deaths and 2 million hospitalizations. Vaccinations are an important part of global public health efforts to meet the Sustainable Developmental Goals of UNDP. “We are highly honored and delighted to become the first rotavirus vaccine from the developing world and India to be WHO Prequalified. We feel proud to dedicate this innovated in India and Made in India vaccine to the world. The true impact of vaccines can be seen, when vaccinations are carried out in affected populations. The Government of India has given a big boost by making ROTAVAC® available to millions in India already," said Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech. “Bharat Biotech’s track record of lifesaving vaccines is a testimony to the company's long-standing commitment to make affordable vaccines for the developing world. ROTAVAC® has been supplied to low income countries at $1.0 / dose, with the feasibility for further ~30% price reductions, based on the procurement of ~100 million doses to these countries,” Dr. Krishna Ella added. ROTAVAC® was developed as a result of a multi-country - multi-partner collaborative model of team science for over 2 decades. This large public private social innovation partnership included the Government of India’s Department of Biotechnology (DBT), the Indian Council of Medical Research, the Indian Institute of Science (IISC), the All India Institute of Medical Sciences (AIIMS), the Translational Health Sciences and Technology Institute (THSTI), the Society for Applied Studies (SAS), Christian Medical College (CMC) Vellore, King Edwards Memorial Hospital (KEM) Pune, Stanford University School of Medicine, the U.S. National Institutes of Health (NIH), the U.S. Centers for Disease Control and Prevention (CDC), Johns Hopkins University and PATH. The ROTAVAC® partnership has resulted in more than 15 international publications, including the pivotal phase III publication in Lancet in 2014. “The novel team science partnership that developed this vaccine serves as a useful model for others to follow,” said Dr. Roger I. Glass, Director of the Fogarty International Center at the U.S. National Institutes of Health, who helped shepherd the process. “The result is an effective, yet economical, vaccine that has the potential to save thousands of children’s lives in Africa and elsewhere.” According to him, Rotavirus is responsible for an estimated 36% of hospitalizations for childhood diarrhea around the world and for an estimated 200,000 deaths in low and middle income countries. WHO prequalification for ROTAVAC® is the result of a rigorous regulatory process. ROTAVAC® has been under development since the year 2000 necessitating investments of around USD 200 million towards product development and dedicated manufacturing infrastructure. The Genome Valley facility has an installed manufacturing capacity of up to 200 million doses / year, and is a scalable model ready to meet global demand. “India’s leadership in developing and introducing its own rotavirus vaccine is commendable and emphasizes a national commitment to improving the health of their children,” said Duncan Steele, deputy director on the Enteric Diarrheal Diseases team at the Bill & Melinda Gates Foundation. “The advent of a locally manufactured, WHO Prequalified rotavirus vaccine offers promise to protect children in India, Africa, the Americas and the rest of Asia from this debilitating disease.” Bharat Biotech has successfully miniaturized the dose volume of ROTAVAC®, to 0.5 ml / dose and is presented in a ready-to-use format, requiring no further reconstitution, similar to oral polio vaccines. The product profile of ROTAVAC® has been optimally designed for the developing world by the developing world to aid ease of administration, reduced training requirements, and with the lowest cold chain footprint for an oral rotavirus vaccine in the world. The cold chain footprint has been reduced to ~3 cm3 / dose, resulting in significant savings in cold chain storage and distribution costs. The 0.5 ml dose volume also reduces the amount of spit-ups by infants when the vaccine is administered. Contacts Bharat Biotech Sheela Panicker, +91 984 980 9594 [email protected] Source: Bharat Biotech DENVER, Jan 24 (Bernama-GLOBE NEWSWIRE) -- Rapid advancements in the molecular diagnostic testing of lung cancer have led to new treatments and greater hope for patients battling lung cancer, the most common cause of cancer death worldwide.
To ensure that clinicians stay apace and provide optimal patient care, three leading medical societies—the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP)—have updated their 2013 evidence-based guideline. Published today in early online release, the “Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors,” continues to set standards for the molecular analysis of lung cancers for test results that effectively guide targeted therapy and treatment. Targeted cancer therapies are drugs or other treatments that block the spread of cancer by interfering with specific molecules that spur that specific cancer’s growth and progression. Patients whose tumors harbor certain, specific molecular alterations may be candidates for targeted tyrosine kinase inhibitor (TKI) therapy, which may improve survival and quality of life. http://mrem.bernama.com/viewsm.php?idm=31003 Combined customers to benefit from broader range of services and greater depth of expertise
KENNESAW, GA, Jan 23 (Bernama-GLOBE NEWSWIRE) -- Brand Industrial Services, known as BrandSafway, has acquired Venko Groep BV, a portfolio company of Mentha Capital, effective January 1, 2018. Moving forward, the company will operate as Venko, A BrandSafway Company and become a part of Brand Energy & Infrastructure Services (Brand) in Europe. “We’re excited to announce the closing of the acquisition of Venko,” said Dave Witsken, President of Energy and Industrial for BrandSafway. “Venko is a leading offshore coatings maintenance provider for platforms in Europe. By leveraging the highly specialized knowledge and capabilities of Venko, we will be able to provide expanded coatings services to Brand’s European customers. At the same time, with our support, Venko will now be able to offer their customers a broader inventory of access equipment and additional industrial services, such as insulation and fireproofing.” http://mrem.bernama.com/viewsm.php?idm=30994 NEW YORK, Jan 23 (Bernama-GLOBE NEWSWIRE) -- The Agency for the Cooperation of Energy Regulators (ACER) has officially extended its contract with Nasdaq (Nasdaq:NDAQ) to continue to leverage Nasdaq’s SMARTS Market Surveillance technology to detect insider trading and market manipulation across the European Union’s wholesale energy markets by digesting and analyzing massive volumes of data from hundreds of power producers, exchanges, operators, and brokers across 28 member states. The new agreement contract extension will continue to allow national regulatory authorities to share data, technology, and expertise, with the aim of creating a cooperative regulatory infrastructure.
Under the contract, SMARTS technology will continue being leveraged to monitor the European wholesale gas and electricity markets, covering both spot trading and derivative markets across Europe in accordance with the obligations under the REMIT legislation. Further, the surveillance technology will support ACER’s efforts in ensuring prices set on wholesale energy markets reflect fair and competitive interplay between supply and demand, with the goal to stifle any profits gained from market abuse. As a truly pan-European development, the partnership allows National Regulatory Authorities to directly leverage the data and technology. The platform is designed in a manner that allows easy sharing of data for investigations across the European Union and for the national regulators to pool their knowledge to fine tune detection algorithms. Several national regulators have already signed up to be part of the technology partnership with the objective of creating a cooperative technology framework for energy market monitoring. “We are proud of our partnership with ACER and its key role in strengthening the integrity and transparency of the EU energy markets,” said Tony Sio, Head of Marketplace & Regulator Surveillance, Market Technology, Nasdaq. “The platform centrally monitors huge volumes of activity across Europe and is designed to foster collaboration across the different national regulators. A cooperative pan-European approach to surveillance ensures that nothing falls through the cracks.” Proven at over 50 marketplaces and regulators, and more than 140 market participants worldwide, Nasdaq’s SMARTS Surveillance technology is the industry benchmark for real-time and T1 solutions for market surveillance, supervision and compliance. About Nasdaq Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of over $9.1 trillion and more than 10,000 corporate clients. To learn more, visit http://nasdaq.com/ambition or http://business.nasdaq.com. NDAQG TD Ameritrade is the first U.S. retail broker dealer to let investors trade select securities 24 hours a day, 5 days a week
OMAHA, Neb., Jan 23 (Bernama-BUSINESS WIRE) -- TD Ameritrade1 is the first U.S. retail broker dealer to enable investors to access equity markets all night long – filling a gap between research and action, and enabling the Company’s growing Asia-based client segment to trade the U.S. markets during their daytime. With this initial launch, qualified TD Ameritrade clients can buy or sell select ETFs from 8 p.m. ET Sunday to 8 p.m. ET Friday. “This is a monumental first for our industry and retail investors,” said Steve Quirk, executive vice president of Trading and Education for TD Ameritrade. “People have busy lives; they want access to their finances anywhere, anytime, and on any device. Online trading made the markets available to anyone, mobile trading made the markets available from anywhere, and now 24-hour trading will make the markets available anytime. We’re focused on innovation that creates more value for investors and ultimately makes their lives – and our industry – better.” The current market schedule leaves a gap between decision making and action. Nearly 70 percent of clients who use TD Ameritrade’s research and education resources do so outside of regular trading hours. Clients performing their research after market hours currently have to wait until the next day to transact based on their research findings. Asia-based investors interested in the U.S. markets must invest during U.S. daytime hours, not their own. http://mrem.bernama.com/viewsm.php?idm=30987 SELANGOR, Jan 23 (Bernama) -- Sungai Long Medical Center (SLMC) has appointed Clinipath Malaysia Sdn Bhd (Clinipath), a wholly-owned subsidiary of Malaysian Genomics Resource Centre Berhad (Malaysian Genomics), to operate its medical laboratory in Bandar Sungai Long, Selangor, Malaysia.
The collaboration with Clinipath will provide SLMC’s doctors and patients with fast and easy access to Clinipath’s comprehensive range of over 1,300 pathology testing solutions. “We have a strong commitment and dedication in providing professional health and medical care for all our patients in Bandar Sungai Long and its vicinity. Having Clinipath on board to operate our medical laboratory is in tandem with our vision to provide the best possible service to our patients,” said Dr Mohamed Ali Abu Bakar, Group CEO, SLMC. “With doctors increasingly requiring more clinical information to diagnose their patients’ ailments and to treat their medical conditions, Clinipath’s advanced pathology tests will be able to help SLMC’s doctors in administering more effective health monitoring and medical treatment for their patients,” said Sasha Nordin, Chief Operating Officer, Malaysian Genomics. SLMC started operations in 2012 and it now offers a comprehensive mix of healthcare services including accident and emergency, general medicine, general surgery, orthopaedics, paediatrics, obstetrics and gynaecology, ENT and ophthalmology. http://mrem.bernama.com/viewsm.php?idm=30996 NEW YORK, Jan 23 (Bernama-BUSINESS WIRE) -- Calvin Klein, Inc., a wholly owned subsidiary of PVH Corp. [NYSE:PVH], today announced its new CALVIN KLEIN UNDERWEAR and CALVIN KLEIN JEANS global multi-media advertising campaign. The campaign represents the latest iteration of the evolution in the CALVIN KLEIN brand’s globally recognized #MYCALVINS call to action: Our Family. #MYCALVINS.
Shot by photographer Willy Vanderperre, the latest chapter of this new campaign features sisters Kim Kardashian West, Khloé Kardashian, Kourtney Kardashian, Kendall Jenner and Kylie Jenner. The siblings are featured wearing styles of CALVIN KLEIN UNDERWEAR that are available in stores and online now, including CALVIN KLEIN Modern Cotton and the new CALVIN KLEIN Body range. In addition, certain members of the family are featured in core styles of CALVIN KLEIN JEANS as well as looks from the Spring 2018 CALVIN KLEIN JEANS collection. The evolved #MYCALVINS concept has family at its center, a display of unity between strong individuals, further emphasized by the symbolism of the traditional American quilt. This campaign captures these bonds and brings to life different ways we can inspire families - both born and made - to connect with one another, and celebrate the things that unite us. mrem.bernama.com/viewsm.php?idm=30997 |
Archives
April 2023
Categories |